Pharmaceutical Technologist - November 2007 - (Page 16)

Aitken// to accelerate their pace of restructuring and rethink sales models. They are also pursuing divergent strategic paths, with some companies focused on higher-margin, though riskier, R&D-based medicines while others diversify by acquiring generics manufacturers, over-the-counter businesses, and device and diagnostic companies. We are also seeing a greater amount of consistency in the efforts of all innovation-based companies to step up attempts to acquire and/or license innovation from others. New organizational approaches are also in evidence. The most successful manufacturers will be those that focus on payers and patients, without losing perspective on the crucial role of physicians. To sustain growth, pharmaceutical companies need to stay ahead of the dynamics that are rebalancing the market place worldwide. This requires a sharper focus on realizing productivity gains from their sales, marketing and launch investments, a comprehensive assessment of their R&D and portfolio strategies to support opportunities in both emerging and mature markets, and a commitment to better demonstrate the value of their medications among key stakeholders. PT Murray Aitken is senior vice president, corporate strategy, at IMS Health, with global responsibility for evaluating and developing plans and actions for the long-term growth of the company. He has more than 20 years of experience advising clients on a variety of strategic, operational, and organizational issues in the pharmaceutical, life sciences, manufacturing and consumer product industries. In brief ● ● ● ● ● The global pharmaceutical market expanded 7% in 2006, with a disproportionate amount of growth in low income countries. Oncology and autoimmune products were fast-growing therapy areas while the quickest growing geographic areas were Eastern Europe, Latin America and India. The variety of global cost containment measures is posing problems and patient opinion is becoming increasingly influential. There appears to be a consistent effort within the industry to acquire and/or license innovation from others and to realign organizational structures. To sustain growth, companies must stay ahead of the shifting dynamics within the global market. 16 November 2007 l pharmaceutical technologist

Table of Contents Feed for the Digital Edition of Pharmaceutical Technologist - November 2007

Pharmaceutical Technologist Contents Editor's Comment News Morpheus Feeling the Pressure Legal Crusaders The Holy-Grail of Start-Up Biotech Special Feature Q&A

Pharmaceutical Technologist - November 2007

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.